
    
      The objective of this clinical trial (STAMP: Safety and Tolerability of Alpha-1 Modified
      Process) is to study the safety and tolerability of Alpha-1 MP in adult Alpha 1-antitrypsin
      deficient subjects as reported over 20 weeks of therapy. The primary objective is to describe
      the nature and frequency of treatment-emergent adverse events with "treatment-emergent"
      defined as any adverse event occurring after the start of the first study drug infusion.
    
  